(Q37960678)

26 August 2017

Is there a future for a Staphylococcus aureus vaccine? (English)

1 reference

26 August 2017

Staphylococcus aureus

1 reference

1 reference

Richard A Proctor

1

1 reference

PubMed ID

22115633

26 August 2017

language of work or name

English

0 references

publication date

21 November 2011

1 reference

26 August 2017

1 reference

26 August 2017

30

1 reference

26 August 2017

19

1 reference

26 August 2017

2921-2927

1 reference

Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Comparative genomics of epidemic versus sporadic Staphylococcus aureus strains does not reveal molecular markers for epidemicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Virulence determinants in Staphylococcus aureus and their involvement in clinical syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

How microorganisms avoid phagocyte attraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Staphylococcus aureus antigens and challenges in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Efficacy of Staphylococcus aureus vaccines for bovine mastitis: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Staphylococcal vaccines and immunotherapy: to dream the impossible dream?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Staphylococcal vaccines and immunotherapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Vaccine assembly from surface proteins of Staphylococcus aureus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

A humanized monoclonal antibody targeting Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Capsule expression and genotypic differences among Staphylococcus aureus isolates from patients with chronic or acute osteomyelitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Staphylococcus aureus microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Molecular characterization of the capsule locus from non-typeable Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

The inverse correlation between Staphylococcus aureus and Streptococcus pneumoniae colonization in infants is not explained by differences in serum antibody levels in the Generation R Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Induction of antibodies by Staphylococcus aureus nasal colonization in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Chronic granulomatous disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Hematologically important mutations: X-linked chronic granulomatous disease (third update)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

The roles of IL-17A in inflammatory immune responses and host defense against pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Recurrent community-associated methicillin-resistant Staphylococcus aureus infections among HIV-infected persons: incidence and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Epidemiology and microbiology of cellulitis and bacterial soft tissue infection during HIV disease: a 10-year survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Th17 cells, Job's syndrome and HIV: opportunities for bacterial and fungal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

IL-17-producing T cells in lung immunity and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Development of a rat central venous catheter model for evaluation of vaccines to prevent Staphylococcus epidermidis and Staphylococcus aureus early biofilms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

IFN-gamma regulated chemokine production determines the outcome of Staphylococcus aureus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

T and B cells are not required for clearing Staphylococcus aureus in systemic infection despite a strong TLR2-MyD88-dependent T cell activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

TLR2 signalling: At the crossroads of commensalism, invasive infections and toxic shock syndrome by Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

NOD2 contributes to cutaneous defense against Staphylococcus aureus through alpha-toxin-dependent innate immune activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Staphylococcal alpha-toxin is a strong inducer of interleukin-17 in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH17 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Whooping cough outbreak hits several US states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Vaccine protection against Staphylococcus aureus pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinatio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Intranasal immunization of mutant toxic shock syndrome toxin 1 elicits systemic and mucosal immune response against Staphylococcus aureus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Autoinduction and signal transduction in the regulation of staphylococcal virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Mutations in agr do not persist in natural populations of methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Capsule-negative Staphylococcus aureus induces chronic experimental mastitis in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

The fibrinogen- and fibronectin-binding domains of Staphylococcus aureus fibronectin-binding protein A synergistically promote endothelial invasion and experimental endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagen-binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Th17 cytokines and vaccine-induced immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Immunity against Staphylococcus aureus cutaneous infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Survival of Staphylococcus aureus inside neutrophils contributes to infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.11.006

1 reference

26 August 2017

1 reference

PubMed ID

22115633